AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
GlobalData on MSN18h
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nodBefore the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
MedPage Today on MSN1d
FDA OKs New Option for Rare Immune-Mediated VasculitisEGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...
Pharmaceutical Technology on MSN1d
MHLW accepts GSK’s multiple myeloma treatment NDA for reviewJapan's Ministry of Health, Labour and Welfare (MHLW) has accepted for review GSK 's new drug application (NDA) for Blenrep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback